- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02956772
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Primary hepatocellular carcinoma (HCC) is one of the most common types of cancer and accounts for significant morbidity and mortality worldwide. Notably, more than half of the new HCC cases and deaths develop in China. Transarterial chemoembolization (TACE) has been proposed as the first-line therapeutic strategy for the treatment of patients with unresectable HCC. However, TACE has several limitations itself which might be potentially associated with tumor metastasis and relapse.
Recent studies have demonstrated that arsenic trioxide (As2O3) can act as the first-line therapeutic option in the treatment of acute promyelocytic leukemia. Thereafter, several small studies in China showed promising clinical benefits when As2O3 is administrated among the HCC patients. With these preliminary results, the investigators are planning to carry out a multicenter randomized controlled trial through which to explore the potential efficacy and safety of adjuvant As2O3 treatment for HCC patients.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Lin Long, Dr.
- Telefonnummer: 86-13507476175
Studieren Sie die Kontaktsicherung
- Name: Hua Xiang, Dr.
- Telefonnummer: 85-13667367061
Studienorte
-
-
Guizhou
-
Guiyang, Guizhou, China
- Guizhou Cancer Hospital
-
Kontakt:
- Shi Zhou, Dr.
- E-Mail: 258600801@qq.com
-
Guiyang, Guizhou, China
- Guizhou Province Tumor Hospital
-
Kontakt:
- Junxiang Li, Dr.
- E-Mail: 258600801@qq.com
-
-
Hunan
-
Changsha, Hunan, China
- Hunan Cancer Hospital
-
Kontakt:
- Guowen LI, Dr.
- E-Mail: liguowen@hnszlyy.com
-
Changsha, Hunan, China
- Xiangya Hospital Central South University
-
Kontakt:
- Chunhui Zhou, Dr.
- E-Mail: zhouchunhui2016@163.com
-
Changsha, Hunan, China, 410001
- Hunan Provincial People's Hospital
-
Kontakt:
- Hua Xiang, Dr.
- Telefonnummer: +86-13667367061
-
Kontakt:
- Lin Long, Dr.
- Telefonnummer: +86-13507476175
- E-Mail: doclongll@163.com
-
Hengyang, Hunan, China
- The First Affiliated Hospital of University of South China
-
Kontakt:
- Youhua Wu, Dr.
- E-Mail: 330270372@qq.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Province Hospital
-
Kontakt:
- Zhen-Qiang Yang, Dr.
- E-Mail: ntdoctoryang@hotmail.com
-
-
Xinjiang
-
Urumqi, Xinjiang, China
- Xinjiang Medical University Cancer Hospital
-
Kontakt:
- Shufa Yang, Dr.
- E-Mail: yangshufa2013@sina.com
-
-
Yunnan
-
Kunming, Yunnan, China
- The Tumor Hospital of Yunnan Province
-
Kontakt:
- Ming Huang, Dr.
- E-Mail: huangming4328@sina.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
- Subject is 18-80 years old.
- Subject has no portal stem vein tumor thrombus.
- Subject has primary middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C inappropriate for surgical resection or other locoregional therapy and still presents with tumor lesions in the liver.
- Subject has evaluable tumor lesion(s) (using Magnetic Resonance Imaging /Computed Tomography) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1: single lesion size ≥5cm or at least one lesion of >3cm in size when 2-3 lesions exist or there are 4 or more lesions.
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤1, Fibrosis index based on 4 factors (FIB-4)≤6 and an expected survival time of 12 weeks or more.
- Haematology: white blood cell count ≥3.0×10^9/L; hemoglobin≥10 g/dL; blood platelet count≥80×10^9/L
- Blood biochemistry: serum albumin ≥2.8 g/dL, total bilirubin ≤2 mg/dL or ≤34.2 umol/L, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 times of upper limit of normal (ULN); amylase and lipase ≤ 1.5 times of ULN; serum creatinine ≤2.0 mg/dL or < 1.5 times of ULN; estimated creatinine clearance ≥60 mL/min.
- International normalized ratio (INR) is ≤ 2.3 or prothrombin time (PT) is ≤3 seconds than upper limit of normal control.
- Echocardiogram indicated a left ventricular ejection fraction (LVEF) of >50%.
- Subject has a liver function Child-Pugh class A or B.
- Subject is not pregnant or lactating.
- Female subjects must be infertile or agree to take effective contraceptives; male subjects and their partners of reproductive potential must also agree to use appropriate contraceptives.
- Subject had no second tumor in the last 5 years, excluding skin basal cell carcinoma or skin squamous carcinoma or any other carcinoma in situ.
- Subject had no history of systemic chemotherapy.
- Subject has no any other concomitant anticancer therapies, such as local radiotherapy, systemic chemotherapy and molecular targeted therapy.
- Subject and (or) guardian is able to understand this study and willing to provide written, informed consent to participate in this clinical study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: TACE plus Arsenic Trioxide
Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21).
TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks.
At least 3 cycles of arsenic trioxide are administrated.
|
After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed.
Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid.
Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
|
Aktiver Komparator: TACE
Patients in this group are to receive a single dose of TACE treatment on day 1.
TACE treatment is repeated every 9 weeks for 27 weeks.
|
After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed.
Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid.
Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Progression free survival
Zeitfenster: 2-year
|
Progression free survival (PFS) is defined as the time interval from the day of the random assignment to the first evidence of progression or death.
|
2-year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Objective response rate
Zeitfenster: 2-year
|
Tumor response is defined as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to RECIST and will be assessed by the investigators.
The tumor objective response rate (ORR) is calculated per treatment arm as the proportion of randomized patients having a confirmed best response of CR or PR.
|
2-year
|
Overall Survival
Zeitfenster: 2-year
|
Overall survival will be measured from the date of randomization up to the date of death of any cause
|
2-year
|
Incidence of adverse events
Zeitfenster: Up to 2 years through study completion
|
Toxicities will be evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v 4.0.
|
Up to 2 years through study completion
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Quality of life using EuroQol five dimensions five levels questionnaire
Zeitfenster: Baseline and week 6, 12, 18, 24 and 30 using EuroQol five dimensions five levels questionnaire
|
Baseline and week 6, 12, 18, 24 and 30 using EuroQol five dimensions five levels questionnaire
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Hua Xiang, Dr., Hunan Provincial People's Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RACE16001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Primäres hepatozelluläres Karzinom
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences CorporationUnbekanntInvasiver Brustkrebs | Duktales Carcinoma in situ der BrustKanada
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Abgeschlossen
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)BeendetBrustkrebsVereinigte Staaten
-
University of AarhusUnbekanntCarcinoma in situ des GebärmutterhalsesDänemark
-
University of Southern CaliforniaBeendetBrustkrebsVereinigte Staaten
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...Aktiv, nicht rekrutierendDuktales Carcinoma in situ der BrustVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossen
-
Brookdale University Hospital Medical CenterUnbekanntCarcinoma in situ des Gebärmutterhalses | Zervikale intraepitheliale Neoplasien | Hochgradige zervikale intraepitheliale NeoplasieVereinigte Staaten
-
Danish Breast Cancer Cooperative GroupDanish Cancer SocietyAktiv, nicht rekrutierendBrustkrebs | Carcinoma in situ der BrustDänemark
-
Thomas Jefferson UniversityRekrutierungBrustkrebs | Invasiver Brustkrebs | Carcinoma in situ der BrustVereinigte Staaten
Klinische Studien zur TACE
-
AZ-VUBUnbekanntDiabetes mellitus, Typ 1Belgien
-
Tallac TherapeuticsRekrutierungFortgeschrittene oder metastatische solide TumorenVereinigte Staaten, Australien
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Taiho Pharmaceutical Co., Ltd.AbgeschlossenLeberkrebsVereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossen
-
Weill Medical College of Cornell UniversityNational Cancer Institute (NCI)AbgeschlossenFortgeschrittener KrebsVereinigte Staaten
-
Novartis PharmaceuticalsZurückgezogen
-
Taiho Pharmaceutical Co., Ltd.AbgeschlossenÜberaktive Blase | Detrusor-UnteraktivitätJapan
-
Taiho Oncology, Inc.Quintiles, Inc.BeendetFortgeschrittenes hepatozelluläres KarzinomJapan
-
Chia Nan University of Pharmacy & ScienceGlac Biotech Co., LtdAbgeschlossenHautkrankheitenTaiwan
-
Taiho Oncology, Inc.ZurückgezogenFortgeschrittenes hepatozelluläres Karzinom